BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 34462665)

  • 1. Analysis of
    Murugan AK; Qasem E; Al-Hindi H; Alzahrani AS
    Mol Clin Oncol; 2021 Oct; 15(4):210. PubMed ID: 34462665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
    Murugan AK; Bojdani E; Xing M
    Biochem Biophys Res Commun; 2010 Mar; 393(3):555-9. PubMed ID: 20171178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
    Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
    J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
    Iñiguez-Ariza NM; Jasim S; Ryder MM; Chintakuntlawar AV; Morris JC; Hilger CR; Menefee ME; Smallridge RC; Karlin NJ; Alcaino C; Bible KC
    J Clin Endocrinol Metab; 2020 Jul; 105(7):e2346-57. PubMed ID: 32421817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
    Murugan AK; Qasem E; Al-Hindi H; Alzahrani AS
    Oncotarget; 2019 Jun; 10(41):4107-4124. PubMed ID: 31289610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
    Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas.
    Jin M; Song DE; Ahn J; Song E; Lee YM; Sung TY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
    Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
    Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
    Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
    Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
    Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
    Sykorova V; Dvorakova S; Vcelak J; Vaclavikova E; Halkova T; Kodetova D; Lastuvka P; Betka J; Vlcek P; Reboun M; Katra R; Bendlova B
    Anticancer Res; 2015 Apr; 35(4):2029-36. PubMed ID: 25862857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of thyroid cancer driven by known and novel ALK fusions.
    Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI
    Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
    Alzahrani AS; Murugan AK; Qasem E; Alswailem MM; AlGhamdi B; Moria Y; Al-Hindi H
    Endocrine; 2019 Jan; 63(1):94-100. PubMed ID: 30269267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.